{"id":"catridecacog","rwe":[{"pmid":"36580025","year":"2023","title":"A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study.","finding":"","journal":"Blood transfusion = Trasfusione del sangue","studyType":"Clinical Study"},{"pmid":"36454477","year":"2023","title":"Correction to: The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTOR(TM)2 trial to a real-world study: a head-to-head comparison.","finding":"","journal":"Journal of thrombosis and thrombolysis","studyType":"Clinical Study"},{"pmid":"36094687","year":"2022","title":"The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTOR(TM)2 trial to a real-world study: a head-to-head comparison.","finding":"","journal":"Journal of thrombosis and thrombolysis","studyType":"Clinical Study"},{"pmid":"30915205","year":"2019","title":"Use of Catridecacog in a patient with severe Factor XIII deficiency undergoing surgery.","finding":"","journal":"Hematology reports","studyType":"Clinical Study"},{"pmid":"25861835","year":"2015","title":"Inflammatory bowel disease therapies discontinued between 2009 and 2014.","finding":"","journal":"Expert opinion on investigational drugs","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"B02BD11","category":"atc"},{"label":"Active","category":"status"},{"label":"Hereditary factor XIII A subunit deficiency","category":"indication"},{"label":"Novo Nordisk A/S","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Novo Nordisk","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CATRIDECACOG","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:12:28.675975+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:12:33.790158+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:12:28.742979+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CATRIDECACOG","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:12:34.252612+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor XIII exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:35.300026+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108282/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:34.960800+00:00"}},"allNames":"novothirteen","offLabel":[],"synonyms":["catridecacog","catridecacog (genetical recombination)","recombinant coagulation factor XIII","NovoThirteen"],"timeline":[{"date":"2012-09-03","type":"positive","source":"DrugCentral","milestone":"EMA approval (Novo Nordisk A/S)"}],"brandName":"Novothirteen","ecosystem":[{"indication":"Hereditary factor XIII A subunit deficiency","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Novothirteen acts as a recombinant factor XIII A subunit, which is a glycoprotein that stabilizes blood clots by cross-linking fibrin molecules."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5134","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CATRIDECACOG","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CATRIDECACOG","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T09:13:30.577884","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:36.595594+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"vonicog alfa","drugSlug":"vonicog-alfa","fdaApproval":"2015-12-08","relationship":"same-class"}],"genericName":"catridecacog","indications":{"approved":[{"name":"Hereditary factor XIII A subunit deficiency","source":"DrugCentral","snomedId":439455002,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"vonicog-alfa","brandName":"vonicog alfa","genericName":"vonicog alfa","approvalYear":"2015","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01862367","phase":"","title":"Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-05-17","conditions":["Congenital Bleeding Disorder","Congenital FXIII Deficiency"],"enrollment":30,"completionDate":"2019-06-26"},{"nctId":"NCT00978380","phase":"PHASE3","title":"Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09-21","conditions":["Congenital Bleeding Disorder","Congenital FXIII Deficiency"],"enrollment":63,"completionDate":"2015-10-20"},{"nctId":"NCT00914589","phase":"PHASE2","title":"Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-07","conditions":["Acquired Bleeding Disorder","Cardiac Surgery Requiring Cardiopulmonary Bypass"],"enrollment":479,"completionDate":"2011-02"},{"nctId":"NCT00713648","phase":"PHASE3","title":"Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-08","conditions":["Congenital Bleeding Disorder","Congenital FXIII Deficiency"],"enrollment":41,"completionDate":"2010-04"},{"nctId":"NCT01230021","phase":"PHASE3","title":"Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-11","conditions":["Congenital Bleeding Disorder","Congenital FXIII Deficiency"],"enrollment":6,"completionDate":"2012-01"},{"nctId":"NCT01847989","phase":"PHASE1","title":"Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-01","conditions":["Congenital Bleeding Disorder","Congenital FXIII Deficiency","Healthy"],"enrollment":50,"completionDate":"2003-05"},{"nctId":"NCT02239146","phase":"PHASE1","title":"Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-10","conditions":["Acquired Bleeding Disorder","Cardiac Surgery Requiring Cardiopulmonary Bypass"],"enrollment":43,"completionDate":"2008-01"},{"nctId":"NCT00056589","phase":"PHASE1","title":"Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-03","conditions":["Congenital Bleeding Disorder","Congenital FXIII Deficiency"],"enrollment":11,"completionDate":"2003-10"},{"nctId":"NCT01082406","phase":"PHASE1","title":"Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-03","conditions":["Congenital Bleeding Disorder","Congenital FXIII Deficiency","Healthy"],"enrollment":51,"completionDate":"2010-07"},{"nctId":"NCT01253811","phase":"PHASE3","title":"Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-01","conditions":["Congenital Bleeding Disorder","Congenital FXIII Deficiency"],"enrollment":6,"completionDate":"2015-03"},{"nctId":"NCT01706159","phase":"PHASE2","title":"A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2012-10","conditions":["Inflammation","Ulcerative Colitis"],"enrollment":20,"completionDate":"2013-07"},{"nctId":"NCT01153997","phase":"PHASE1","title":"Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-06","conditions":["Acquired Bleeding Disorder","Cardiac Surgery Requiring Cardiopulmonary Bypass","Healthy"],"enrollment":24,"completionDate":"2010-08"},{"nctId":"NCT01848002","phase":"PHASE1","title":"Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-05","conditions":["Congenital Bleeding Disorder","Congenital FXIII Deficiency","Healthy"],"enrollment":24,"completionDate":"2003-08"}],"_emaApprovals":[{"date":"2012-09-03","status":"Authorised","company":"Novo Nordisk A/S"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"30297","NDDF":"015338","UNII":"NU23Q531G1","INN_ID":"8817","RXNORM":"1488293","UMLSCUI":"C3709760","chemblId":"CHEMBL2108282","ChEMBL_ID":"CHEMBL2108282","KEGG_DRUG":"D10532","DRUGBANK_ID":"DB09310","SNOMEDCT_US":"22771000122108"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Novo Nordisk","relationship":"Current Owner"}],"publicationCount":6,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"B02BD11","allCodes":["B02BD11"]},"biosimilarFilings":[],"recentPublications":[{"date":"2023 Jul","pmid":"36580025","title":"A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study.","journal":"Blood transfusion = Trasfusione del sangue"},{"date":"2023 Jan","pmid":"36454477","title":"Correction to: The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTOR(TM)2 trial to a real-world study: a head-to-head comparison.","journal":"Journal of thrombosis and thrombolysis"},{"date":"2022 Nov","pmid":"36094687","title":"The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTOR(TM)2 trial to a real-world study: a head-to-head comparison.","journal":"Journal of thrombosis and thrombolysis"},{"date":"2019 Feb 19","pmid":"30915205","title":"Use of Catridecacog in a patient with severe Factor XIII deficiency undergoing surgery.","journal":"Hematology reports"},{"date":"2015","pmid":"25861835","title":"Inflammatory bowel disease therapies discontinued between 2009 and 2014.","journal":"Expert opinion on investigational drugs"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Novo Nordisk","companyId":"novo-nordisk","modality":"Recombinant protein","firstApprovalDate":"2012","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:36.595594+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}